New pill aims to tame Hormone-Driven high blood pressure

NCT ID NCT07470983

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests a new drug called HRS-1780 in 60 adults with primary aldosteronism, a condition where the adrenal glands make too much of a hormone that raises blood pressure. Participants will receive either HRS-1780 or a placebo to see if the drug safely lowers blood pressure and controls hormone levels. The trial is double-blind, meaning neither patients nor doctors know who gets the real drug.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
HRS-1780 (a drug taken as a tablet)
What this could lead to
If it works, this could offer a new treatment option to control blood pressure and hormone levels in people with primary aldosteronism.
What could go wrong
This is an early Phase 2 trial with only 60 people, so results may not apply broadly. The drug may not work better than placebo or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY ALDOSTERONISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital of Chongqing Medical University

    RECRUITING

    Chongqing, Chongqing Municipality, 400016, China

  • The First Affiliated Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, Henan, 450052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.